Project Grant R01CA289978
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$607K
Federal Agency
National Cancer Institute
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $674,440 to the University of Miami to conduct research on defining the genomic events that differentiate benign and malignant multiple myeloma precursor conditions. The 5-year project, running from February 2025 through January 2030, aims to use advanced single-cell whole genome sequencing and immune microenvironment analysis to comprehensively characterize the subclonal genomic...
This R01 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) for $1,419,108 supports research to advance the understanding of how a novel neoadjuvant therapy impacts the immune system in patients with solid tumors, using refractory melanoma as a model. The key objectives are to: Gain insight into how blocking the Semaphorin 4D (SEMA4D) signaling pathway, when combined with immune checkpoint blockade, impacts the infiltration and function of...
This $1,128,990 Cooperative Agreement award from the National Cancer Institute (CFDA 93.353 - 21st Century Cures Act - Beau Biden Cancer Moonshot) will fund the Myeloma Multidimensional Precancer Atlas (MMPCA) project at the Dana-Farber Cancer Institute. The project aims to construct a comprehensive spatial and temporal atlas of precursor stages of multiple myeloma (MM) to understand genomic and microenvironmental alterations across the disease spectrum. Key objectives include: Mapping spatial...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $691,118 in funding to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to establish a prospective cohort study of real-world multiple myeloma patients treated with chimeric antigen receptor (CAR) T-cell therapy. The study aims to evaluate the relationships between psychosocial factors (e.g., depression, anxiety, social support) and...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $620,521 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, FL to develop an integrated mathematical modeling approach to study how the aging bone ecosystem impacts the evolution and treatment response of multiple myeloma. The key objectives are to: 1) Use spatial transcriptomic analysis and in vitro data to "age" a hybrid...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Trustees of the University of Pennsylvania provides $621,156 over a 5-year period starting January 1, 2025 to identify novel regulators of endoplasmic reticulum (ER) homeostasis in malignant plasma cells that can be targeted to induce cell death or prevent upstream events driving multiple myeloma. The key objectives are to: 1) investigate how disrupting purinergic receptor...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $427,095 to Northeastern University to develop a novel microfluidic droplet-based platform (MDP) technology. The MDP will generate and analyze a 3D biomimetic multicellular immunogenic tumor model to: Establish multiple levels of hypoxia within the same tumor-chip for parallel processing. Investigate spatiotemporal interaction between the...
The National Cancer Institute (NCI) awarded a $100,760 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research in New York, NY. The grant, running from January 1, 2025 to December 31, 2028, will support the development of a targeted nanoparticle platform to co-deliver small interfering RNA (siRNA) sequences targeting the tumor microenvironment proteins cyclophilin A and E-selectin. This innovative approach aims to inhibit...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $442,236 to the University of Alabama at Birmingham to conduct research aimed at understanding the role of RNA modification pathways in promoting melanoma metastasis. The key objectives are to determine how the YTHDF1 RNA-binding protein and its downstream targets, such as IMPDH1 and TRKB/BDNF, contribute to melanoma cell anoikis resistance and suppression of anti-tumor immunity mediated by...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $499,902 to Rowan University to develop a novel MCL-1 inhibitor, KS18, and investigate its potential to reverse chemotherapeutic resistance in multiple myeloma (MM). The key objectives are to: 1) determine if MCL-1 inhibition via KS18 can reverse acquired resistance to standard MM treatments like bortezomib in vitro, 2) evaluate if KS18 can overcome bortezomib resistance in MM...